rAAV2 Vector Delivery of ApoE ε2 to Ependymal Cells
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene therapy methods face challenges in effectively treating central nervous system diseases, particularly Alzheimer's disease, due to the inability of therapeutic proteins to cross the blood-brain barrier and achieve widespread distribution.
Innovation Solution
The use of an rAAV2 particle comprising an AAV2 capsid protein and a vector encoding a protective ApoE ε2 isoform protein, administered to ependymal cells in the cerebrospinal fluid, which secretes the ApoE ε2 protein to treat Alzheimer's disease, leveraging the ependymal cells' ability to secrete the protein into the CSF for central nervous system delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If therapeutic proteins are delivered intravenously, then they can be administered systemically, but they cannot cross the blood-brain barrier to reach the central nervous system
Solution Approach 1:
The patent uses ependymal cells as intermediary carriers that are accessible via intravenous injection. These cells internalize the therapeutic protein from the bloodstream and transport it across the blood-brain barrier, mediating delivery to the central nervous system without requiring direct crossing of the barrier by the therapeutic protein itself
Solution Approach 2:
The patent exploits the natural physiological function of ependymal cells to perform the delivery task. These cells naturally transport substances from the bloodstream into the cerebrospinal fluid and brain tissue, so by utilizing their endogenous transport mechanisms, the system achieves self-service delivery without requiring external intervention to cross the blood-brain barrier
2Reliability
If therapeutic proteins are delivered directly to the brain, then they can reach the central nervous system, but they are not widely distributed throughout the brain tissue
Solution Approach 1:
The patent achieves widespread distribution by utilizing the ependymal cell network that lines the entire ventricular system of the brain. As these cells are distributed throughout the central nervous system, they serve multiple delivery locations simultaneously, enabling the therapeutic protein to reach various brain regions through a single administration route
3Reliability
If gene therapy is used to treat Alzheimer's disease, then therapeutic proteins can be produced in situ, but the blood-brain barrier prevents systemic delivery from reaching the brain
Solution Approach 1:
The patent uses ependymal cells as intermediary carriers that are accessible via intravenous injection. These cells internalize the therapeutic protein from the bloodstream and transport it across the blood-brain barrier, mediating delivery to the central nervous system without requiring direct crossing of the barrier by the therapeutic protein itself
Solution Approach 2:
Instead of attempting to deliver therapeutic proteins directly across the blood-brain barrier from the bloodstream, the patent inverts the approach by using ependymal cells to actively transport the proteins from the bloodstream into the brain tissue, reversing the traditional delivery direction and overcoming the barrier through cellular mediation
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach achieves significant reduction in amyloid plaque density and associated neurotoxicity, demonstrating a therapeutic effect by modulating amyloid deposition and clearance, thereby potentially offering a treatment for Alzheimer's disease.
Implementation Method 1
the rAAV particle is administered to an ependymal cell thereby delivering the nucleic acid to the ependymal cell
Data Source
Figure 1A~1B
Figure 2
Figure 3
AI summary
The present disclosure provides methods of delivering a protective ApoE isoform to the central nervous system of a mammal, comprising administering to the cerebrospinal fluid (CSF) of the mammal an rAAV particle comprising an AAV capsid protein and a vector comprising a nucleic acid encoding the protective ApoE isoform inserted between a pair of AAV inverted terminal repeats in a manner effective to infect ependymal cells in the non-rodent mammal such that the ependymal cells secrete the ApoE into the CSF of the mammal.